Network Meta-analysis of Six Chinese Patent Medicines in Treatment of Knee Osteoarthritis
Objective:To provide evidence based reference for the evaluation of efficacy and safety of combing six Chinese patent medicines(Bi-qi,Jin-tian-ge,Jin-wu-gu-tong,Wang-bi tablets,Teng-huang-jian-gu,Xian-ling-gu-bao)with NASIDs by network meta-analysis.Methods:PubMed,Cochrane Library,Web of Science,CNKI,Wangfang Data and CQVIP were retrieved to pick RCTs of Six Chinese patent medicines in the treatment of knee osteoarthritis from the date of construction to November 30,2023.The bias risk assessment tool recommended by Cochrane was used to evaluate the quality of the included RCTs.Results:Nineteen RCTs were included.The result showed that in terms of the overall efficacy,the optimal top three therapeutic schedules were Biqi+NASIDs,Jinwugutong+NASIDs and Wangbi tablets+NASIDs.In terms of visual analogue pain score,the optimal top three therapeutic schedules were Jinwugu-tong+NASIDs,Xianlinggubao+NASIDs and Tenghuangji-angu+NASIDs.In terms of WOMAC,the optimal top three therapeutic schedules were Ten-ghuangjiangu+NASIDs,Jintiange+NASIDs and Xianlinggubao+NASIDs.In terms of adverse reactions,the optimal top three therapeutic schedules were Tenghuangjiangu+NASIDs,Biqi+NASIDs and Xianlinggubao+NASIDs.Conclusion:Combination treatment of Chinese patent medicines and NASIDs can relieve symptoms caused by knee osteoarthritis and has better medical safety.
NETL
NSTL
万方数据
